12.13
Passage de la perfusion intraveineuse à l’administration orale : méthodes de conversion
Le développement de formulations à libération prolongée a facilité le passage de la voie intraveineuse à la voie orale, offrant une approche plus prat…
La disponibilité de formulations à libération prolongée a permis la conversion des perfusions intraveineuses aux médicaments oraux.
L’arrêt de la perfusion IV diminue la concentration plasmatique de médicament par la cinétique d’élimination du premier ordre.
La dose orale doit contrer ce déclin pour atteindre une nouvelle concentration à l’état stable.
Pour les patients stabilisés par perfusion intraveineuse, deux méthodes sont utilisées pour calculer les schémas de posologie orale.
La première méthode suppose que la concentration plasmatique en régime permanent après perfusion IV correspond à la concentration moyenne souhaitée en plasma à régime permanent après plusieurs doses orales. Ici, la concentration moyenne à l’état stationnaire dépend de la forme selée du médicament, de la biodisponibilité fractionnaire, de la dissipation et du taux de dosage.
Une perfusion intraveineuse d’aminophylline à 34 mg par heure correspond à une dose orale de théophylline de 28,9 mg par heure. Sur 24 heures, cela donne une dose quotidienne totale de théophylline d’environ 700 mg.
La seconde méthode assimile le taux d’infusion intraveineuse au taux de dosage oral souhaité. Ici, le taux de dosage oral peut être calculé simplement en multipliant la dose totale quotidienne IV par la forme saline du médicament.
View the full transcript and gain access to JoVE Core videos
Q1: Why is converting from IV infusion to oral medication necessary?
Extended-release formulations enable safer, more convenient patient transitions from IV to oral therapy while maintaining therapeutic drug levels. This shift improves quality of life by allowing self-administration at home rather than requiring continuous hospital infusions. The conversion preserves efficacy and prevents adverse effects through careful pharmacokinetic management.
Q2: What happens to drug concentration when an IV infusion is discontinued?
Discontinuing IV infusion causes plasma drug concentration to decline following first-order elimination kinetics. Oral dosing must be carefully calculated to counteract this drop and establish a new steady state. Extended-release formulations help by allowing steady drug release over time, mimicking constant levels achieved with IV infusions.
Q3: What is the first method for calculating oral dosage during IV-to-oral conversion?
The first method matches the steady-state plasma concentration achieved with IV infusion to the desired average concentration with oral dosing. This calculation incorporates the drug's salt form, fractional bioavailability, clearance, and dosing rate. For example, an IV aminophylline infusion of 34 mg/hour converts to approximately 700 mg daily oral theophylline dose.
Q4: How does the second conversion method differ from the first?
The second method directly equates the IV infusion rate to the desired oral dosing rate by multiplying the total daily IV dose by the drug's salt form. While simpler to apply, this approach does not account for differences in bioavailability or dosing schedule effects, potentially leading to inaccuracies in maintaining therapeutic drug levels compared to the first method.
Q5: What parameters must be considered when calculating oral dosage from IV infusion?
Critical parameters include the drug's salt factor, fractional bioavailability, clearance rate, and desired dosing frequency. For theophylline with 100% bioavailability, a 28.9 mg/hour IV infusion rate yields approximately 700 mg daily oral dose, often divided into two 350 mg controlled-release doses administered every 12 hours to maintain therapeutic levels.
Q6: Why are extended-release formulations important for IV-to-oral conversion?
Extended-release formulations enable steady drug release over extended periods, mimicking constant plasma levels achieved with IV infusions. This sustained delivery maintains therapeutic drug concentrations throughout the dosing interval, reducing fluctuations and improving patient compliance compared to immediate-release oral medications requiring frequent dosing.
Q7: What role does bioavailability play in converting IV to oral dosing?
Bioavailability determines how much oral drug reaches systemic circulation compared to IV administration. The first conversion method accounts for bioavailability differences through the fractional bioavailability factor, ensuring equivalent therapeutic exposure. Ignoring bioavailability, as in the simpler second method, may result in subtherapeutic or toxic drug levels.